 Christine Phillips
Concepts (75)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2023 | 269 | 3.880 |
Why?
| | Immunotherapy, Adoptive | 10 | 2023 | 194 | 2.100 |
Why?
| | Receptors, Antigen, T-Cell | 11 | 2023 | 630 | 1.740 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 66 | 1.440 |
Why?
| | Leukemia, Myeloid, Acute | 4 | 2020 | 538 | 1.320 |
Why?
| | Antigens, CD19 | 6 | 2023 | 97 | 1.250 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 2020 | 83 | 1.090 |
Why?
| | Cytarabine | 1 | 2020 | 52 | 0.690 |
Why?
| | DNA Virus Infections | 1 | 2017 | 4 | 0.590 |
Why?
| | DNA Viruses | 1 | 2017 | 10 | 0.590 |
Why?
| | Nervous System Diseases | 1 | 2020 | 253 | 0.560 |
Why?
| | DNA, Viral | 1 | 2017 | 351 | 0.500 |
Why?
| | Polymerase Chain Reaction | 1 | 2017 | 1001 | 0.470 |
Why?
| | Child | 17 | 2023 | 18486 | 0.460 |
Why?
| | Biomarkers, Tumor | 1 | 2020 | 1048 | 0.450 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 1919 | 0.410 |
Why?
| | Azacitidine | 1 | 2013 | 130 | 0.390 |
Why?
| | Remission Induction | 3 | 2023 | 240 | 0.360 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 57 | 0.350 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2021 | 154 | 0.340 |
Why?
| | Recurrence | 5 | 2023 | 952 | 0.330 |
Why?
| | Child, Preschool | 9 | 2022 | 9130 | 0.290 |
Why?
| | Polymorphism, Genetic | 1 | 2010 | 621 | 0.290 |
Why?
| | Stem Cell Transplantation | 2 | 2019 | 151 | 0.250 |
Why?
| | Adolescent | 10 | 2022 | 17903 | 0.230 |
Why?
| | Infant | 6 | 2022 | 7975 | 0.230 |
Why?
| | Humans | 19 | 2023 | 115612 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2128 | 0.200 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 58 | 0.190 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2021 | 63 | 0.180 |
Why?
| | Gene Rearrangement | 1 | 2021 | 135 | 0.180 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2023 | 374 | 0.180 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2020 | 72 | 0.170 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2021 | 96 | 0.170 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2020 | 57 | 0.170 |
Why?
| | Retrospective Studies | 7 | 2023 | 12608 | 0.160 |
Why?
| | Antibodies, Bispecific | 1 | 2019 | 33 | 0.160 |
Why?
| | Neoplasm, Residual | 1 | 2019 | 105 | 0.160 |
Why?
| | Down Syndrome | 1 | 2022 | 336 | 0.140 |
Why?
| | Male | 8 | 2021 | 55967 | 0.140 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2017 | 123 | 0.140 |
Why?
| | Infant, Newborn | 3 | 2019 | 5059 | 0.130 |
Why?
| | Survival Rate | 1 | 2020 | 1650 | 0.130 |
Why?
| | Comorbidity | 1 | 2020 | 1473 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1147 | 0.120 |
Why?
| | Young Adult | 6 | 2022 | 10487 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2021 | 9159 | 0.110 |
Why?
| | Drug Evaluation | 1 | 2013 | 79 | 0.110 |
Why?
| | DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2013 | 14 | 0.110 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 1 | 2013 | 27 | 0.110 |
Why?
| | RNA, Neoplasm | 1 | 2013 | 80 | 0.110 |
Why?
| | Adult | 6 | 2023 | 30726 | 0.100 |
Why?
| | Neutropenia | 1 | 2013 | 127 | 0.100 |
Why?
| | Prospective Studies | 2 | 2022 | 6264 | 0.100 |
Why?
| | Salvage Therapy | 1 | 2013 | 128 | 0.100 |
Why?
| | Prognosis | 1 | 2020 | 3339 | 0.100 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 397 | 0.100 |
Why?
| | Bone Marrow | 1 | 2013 | 249 | 0.100 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4440 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1127 | 0.090 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 385 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 1893 | 0.080 |
Why?
| | Female | 6 | 2021 | 59931 | 0.080 |
Why?
| | MicroRNAs | 1 | 2013 | 607 | 0.070 |
Why?
| | Genotype | 1 | 2010 | 1787 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2010 | 3023 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1361 | 0.050 |
Why?
| | Vidarabine | 1 | 2022 | 27 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 58 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 84 | 0.050 |
Why?
| | Cost of Illness | 1 | 2021 | 257 | 0.040 |
Why?
| | Chronic Disease | 1 | 2023 | 1598 | 0.040 |
Why?
| | United States | 2 | 2023 | 12297 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1756 | 0.030 |
Why?
| | Incidence | 1 | 2019 | 2335 | 0.030 |
Why?
|
|
Phillips's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|